10-Q: HeartSciences Faces Financial Hurdles Amidst Merger Talks

HeartSciences Inc. reports continued operating losses and a going concern warning in its latest 10-Q filing, even as it advances its MyoVista Insights platform and pursues a merger with Fortitude Mining Holdings.

Summary

• HeartSciences Inc. filed its Form 10-Q for the quarterly period ended July 31, 2026.
• The company reported a net loss of $3,172,344 for the three months ended July 31, 2026, compared to a net loss of $2,054,994 for the same period in 2025.
• As of July 31, 2026, the company had an accumulated deficit of $88.4 million, a stockholders' deficit of $2.0 million, and a working capital deficit of $4.8 million.
• These financial conditions raise substantial doubt about the company's ability to continue as a going concern.
• The company is pursuing a merger with Fortitude Mining Holdings, Inc., with a planned closing in the second half of 2026, subject to shareholder approval.
• A private placement with Fortitude on August 12, 2026, raised approximately $1.0 million for operating expenses.
• The company received a notice from Nasdaq on August 4, 2026, for non-compliance with the minimum stockholders' equity requirement, with a plan to regain compliance expected to be based on the proposed merger.
• The company is focusing its resources on the MyoVista Insights platform and has recorded a reserve against MyoVista wavECG inventory.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to significant ongoing losses, a substantial accumulated deficit, a working capital deficit, and a going concern warning, despite progress on the MyoVista Insights platform and a pending merger.

Positives

• The MyoVista Insights platform received Epic Toolbox designation in March 2026, potentially facilitating adoption within Epic-enabled health systems.
• In June 2026, MyoVista Insights version 1.3 was launched, introducing an AI-ECG Algorithm Marketplace, marking the first time a cleared AI-ECG algorithm is available through the platform.
• The company signed two commercial agreements in May 2026 to deploy the MyoVista Insights platform.
• A private placement with Fortitude on August 12, 2026, raised approximately $1.0 million to fund operating expenses leading up to the expected merger closing.
• The company was granted a European patent in June 2026 covering machine-learning models for estimating echocardiogram parameters.

Negatives

• The company reported a net loss of $3,172,344 for the three months ended July 31, 2026, a 54% increase from the prior year's $2,054,994 loss.
• Total operating expenses increased by 57% to $2,940,430 from $1,875,259 in the prior year period, driven by a significant rise in selling, general, and administrative expenses.
• The company has an accumulated deficit of $88.4 million as of July 31, 2026.
• Stockholders' deficit stands at $2.0 million as of July 31, 2026.
• Working capital deficit is $4.8 million as of July 31, 2026.
• The company has a going concern warning due to recurring losses and negative cash flows.
• The company received a Nasdaq non-compliance notice for minimum stockholders' equity, with a plan to regain compliance contingent on the proposed merger.
• A reserve of $0.3 million was recorded against MyoVista wavECG inventory due to an uncertain commercialization timeline.

Risks

• The company has a limited operating history and has incurred significant operating losses since inception, with continued losses anticipated.
• Failure to complete the proposed merger with Fortitude would likely materially adversely affect the company's business, financial condition, results of operations, and stock price.
• The company's ability to continue as a going concern is subject to substantial doubt, requiring additional capital through equity, debt, or strategic partnerships, with no assurance of availability.
• The company is not in compliance with Nasdaq's minimum stockholders' equity requirement, risking delisting if compliance is not regained.
• The company has identified material weaknesses in its internal control over financial reporting, including insufficient GAAP and SEC accounting resources and insufficient staff for segregation of duties.
• The outcome of the FDA's review of the MyoVista wavECG 510(k) submission is uncertain and could materially adversely affect the company's reputation and prospects.
• The company's future operating results are expected to be principally dependent on the successful development and commercialization of MyoVista Insights.

Future Outlook

The company expects to continue devoting significant capital resources to R&D, clinical studies, and go-to-market strategies. It anticipates needing to raise additional capital through equity, debt, or strategic partnerships. The successful development and commercialization of MyoVista Insights is critical for future operating results. The completion of the merger with Fortitude is expected in the second half of 2026 and is subject to closing conditions.

Management Comments

• Management believes that current resources would be insufficient to fund operations for the next twelve months following the issuance of these financial statements.
• Management plans include raising capital through the sale of additional equity securities, debt, or capital inflows from strategic partnerships.
• Management believes that the plan to consummate the Proposed Transaction will serve as a basis for the plan to regain compliance with Nasdaq listing rules.
• Management believes the actions taken will effectively remediate the material weaknesses in internal controls, but remediation will not be considered complete until controls are in place, tested, and deemed effective.

Industry Context

StockSavvy.ai notes that HeartSciences operates in the evolving healthcare IT sector, specifically focusing on AI integration in electrocardiography. The company's strategic shift towards its MyoVista Insights platform, a cloud-native, device-agnostic solution, aligns with industry trends favoring software-based solutions and AI-driven diagnostics over proprietary hardware. The Epic Toolbox designation is a positive step for integration into major healthcare IT ecosystems.

Comparison to Industry Standards

• The company's net loss of $3.2 million for the quarter and accumulated deficit of $88.4 million are significant for a company at this stage, indicating a high cash burn rate typical of early-stage medical technology firms, but requiring substantial future funding.
• The focus on a cloud-based, device-agnostic platform like MyoVista Insights aligns with industry trends seen in companies like Philips (e.g., IntelliSpace Cardiovascular) and GE Healthcare, which offer integrated diagnostic data management and AI capabilities.
• The Nasdaq minimum equity requirement of $2.5 million is a standard benchmark for listing on the Capital Market, which HeartSciences is currently failing to meet, a common challenge for development-stage companies.
• The company's revenue of $2,100 for the quarter is extremely low, reflecting its pre-commercialization or early-commercialization stage, typical for companies in this sector before widespread market adoption.

Legal Proceedings

• The company is a party to a legal proceeding where the claimant is seeking damages of $180,000, plus prejudgment interest, costs, and attorney fees. No liability has been recorded as a loss is not currently considered probable.

Related Party Transactions

• The company entered into a merger agreement with Fortitude Mining Holdings, Inc., and subsequently conducted a private placement with Fortitude.
• The company has outstanding debt with Streeterville Capital, LLC, which has involved exchanges of debt for common stock.
• The company has a royalty agreement with its founder, Guangren Gary Chen, related to MyoVista wavECG device sales.
• The company has a loan and security agreement with Front Range Ventures LLC (FRV) and John Q. Adams, Sr., both of whom were shareholders at the time of issuance.

Stakeholder Impact

• Shareholders: The pending merger with Fortitude and Nasdaq compliance issues create uncertainty. Dilution is a risk due to potential future capital raises.
• Creditors: The company's going concern status and working capital deficit may impact its ability to meet debt obligations.
• Employees: The company's financial situation and the pending merger could affect job security and future compensation, particularly with stock-based awards tied to vesting and merger completion.
• Suppliers: The company's financial instability could affect its ability to pay suppliers on time.

Next Steps

• Obtain shareholder approval for the proposed merger with Fortitude Mining Holdings, Inc.
• Submit a plan to Nasdaq by September 18, 2026, to regain compliance with minimum stockholders' equity requirements.
• Continue development and commercialization efforts for the MyoVista Insights platform.
• Seek additional capital through equity, debt, or strategic partnerships to fund operations for the next twelve months.
• Continue to evaluate the MyoVista wavECG inventory and its net realizable value.

Key Dates

Recommendation

The company exhibits significant financial distress, including a substantial net loss, accumulated deficit, working capital deficit, and a going concern warning. While progress on the MyoVista Insights platform and a pending merger offer potential upside, the immediate financial risks and Nasdaq compliance issues outweigh these positives, suggesting a sell recommendation until a clearer path to profitability and stability emerges.

Keywords

HeartSciences, MyoVista Insights, MyoVista wavECG, AI-ECG, Merger, Fortitude Mining, Nasdaq Compliance, Going Concern